{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:08:15Z","timestamp":1792822095732,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Microbiol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00284-026-04892-4","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T06:29:06Z","timestamp":1776320946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["\u03b2-Lactamase-Driven Resistance to Cefiderocol in Carbapenem-Resistant Pseudomonas aeruginosa and its Reversal by Avibactam"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7036-0587","authenticated-orcid":false,"given":"Abdullah","family":"Tozluyurt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"4892_CR1","unstructured":"Organization WH (2024) WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance, to guide research, development, and strategies to prevent and control antimicrobial resistance. World Health Organization"},{"issue":"7","key":"4892_CR2","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1111\/j.1462-2920.2011.02469.x","volume":"13","author":"S De Bentzmann","year":"2011","unstructured":"De Bentzmann S, Pl\u00e9siat P (2011) The Pseudomonas aeruginosa opportunistic pathogen and human infections. Environ Microbiol 13(7):1655\u20131665","journal-title":"Environ Microbiol"},{"issue":"6","key":"4892_CR3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/ppul.21011","volume":"44","author":"T Bjarnsholt","year":"2009","unstructured":"Bjarnsholt T, Jensen P\u00d8, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, Pressler T, Givskov M, H\u00f8iby N (2009) Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 44(6):547\u2013558","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"4892_CR4","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/apm.13010","volume":"128","author":"S Crone","year":"2020","unstructured":"Crone S, Vives-Fl\u00f3rez M, Kvich L, Saunders AM, Malone M, Nicolaisen MH, Mart\u00ednez\u2010Garc\u00eda E, Rojas\u2010Acosta C, Catalina Gomez\u2010Puerto M, Calum H (2020) The environmental occurrence of Pseudomonas aeruginosa. APMIS 128(3):220\u2013231","journal-title":"APMIS"},{"key":"4892_CR5","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S238811","author":"RM Abd El-Baky","year":"2020","unstructured":"Abd El-Baky RM, Masoud SM, Mohamed DS, Waly NG, Shafik EA, Mohareb DA, Elkady A, Elbadr MM, Hetta HF (2020) Prevalence and some possible mechanisms of colistin resistance among multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. Infect Drug Resist. https:\/\/doi.org\/10.2147\/IDR.S238811","journal-title":"Infect Drug Resist"},{"key":"4892_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jhin.2023.06.013","volume":"139","author":"V Sch\u00e4rer","year":"2023","unstructured":"Sch\u00e4rer V, Meier M-T, Schuepbach RA, Zinkernagel AS, Boumasmoud M, Chakrakodi B, Brugger SD, Fr\u00f6hlich MR, Wolfensberger A, Sax H (2023) An intensive care unit outbreak with multi-drug-resistant Pseudomonas aeruginosa\u2013spotlight on sinks. J Hosp Infect 139:161\u2013167","journal-title":"J Hosp Infect"},{"issue":"2","key":"4892_CR7","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/infdis\/jiad318","volume":"229","author":"AJ Sundermann","year":"2024","unstructured":"Sundermann AJ, Rangachar Srinivasa V, Mills EG, Griffith MP, Waggle KD, Ayres AM, Pless L, Snyder GM, Harrison LH, Van Tyne D (2024) Two artificial tears outbreak-associated cases of extensively drug-resistant Pseudomonas aeruginosa detected through whole genome sequencing\u2013based surveillance. J Infect Dis 229(2):517\u2013521","journal-title":"J Infect Dis"},{"issue":"4","key":"4892_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad098","volume":"5","author":"JA Karlowsky","year":"2023","unstructured":"Karlowsky JA, Lob SH, Hawser SP, Kothari N, Siddiqui F, Alekseeva I, DeRyke CA, Young K, Motyl MR, Sahm DF (2023) Activity of ceftolozane\/tazobactam and imipenem\/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in central and northern Europe (Belgium, Norway, Sweden, Switzerland)\u2014SMART 2017\u201321. JAC-Antimicrobial Resistance 5(4):dlad098","journal-title":"JAC-Antimicrobial Resistance"},{"issue":"7","key":"4892_CR9","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00194-23","volume":"67","author":"MJ Satlin","year":"2023","unstructured":"Satlin MJ, Simner PJ, Slover CM, Yamano Y, Nagata TD, Portsmouth S (2023) Cefiderocol treatment for patients with multidrug-and carbapenem-resistant Pseudomonas aeruginosa infections in the compassionate use program. Antimicrob Agents Chemother 67(7):e00194-00123","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"4892_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/life13071427","volume":"13","author":"S Domingues","year":"2023","unstructured":"Domingues S, Lima T, Saavedra MJ, Da Silva GJ (2023) An overview of Cefiderocol\u2019s therapeutic potential and underlying resistance mechanisms. Life 13(7):1427","journal-title":"Life"},{"issue":"11","key":"4892_CR11","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1093\/jac\/dky317","volume":"73","author":"A Ito","year":"2018","unstructured":"Ito A, Nishikawa T, Ota M, Ito-Horiyama T, Ishibashi N, Sato T, Tsuji M, Yamano Y (2018) Stability and low induction propensity of cefiderocol against chromosomal AmpC \u03b2-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae. J Antimicrob Chemother 73(11):3049\u20133052","journal-title":"J Antimicrob Chemother"},{"key":"4892_CR12","doi-asserted-by":"crossref","unstructured":"Simner PJ, Beisken S, Bergman Y, Posch AE, Cosgrove SE, Tamma PD (2021) Cefiderocol activity against clinical Pseudomonas aeruginosa isolates exhibiting ceftolozane-tazobactam resistance. Open Forum Infectious Diseases. Oxford University Press US, p ofab311","DOI":"10.1093\/ofid\/ofab311"},{"issue":"3","key":"4892_CR13","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/jac\/dkv402","volume":"71","author":"A Ito","year":"2016","unstructured":"Ito A, Kohira N, Bouchillon SK, West J, Rittenhouse S, Sader HS, Rhomberg PR, Jones RN, Yoshizawa H, Nakamura R (2016) In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting Gram-negative bacteria. J Antimicrob Chemother 71(3):670\u2013677","journal-title":"J Antimicrob Chemother"},{"key":"4892_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","volume":"79","author":"GG Zhanel","year":"2019","unstructured":"Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA (2019) Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli. Drugs 79:271\u2013289","journal-title":"Drugs"},{"issue":"1","key":"4892_CR15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1099\/jmm.0.081802-0","volume":"64","author":"F Toval","year":"2015","unstructured":"Toval F, Guzm\u00e1n-Marte A, Madriz V, Somogyi T, Rodr\u00edguez C, Garc\u00eda F (2015) Predominance of carbapenem-resistant Pseudomonas aeruginosa isolates carrying bla IMP and bla VIM metallo-\u03b2-lactamases in a major hospital in Costa Rica. J Med Microbiol 64(1):37\u201343","journal-title":"J Med Microbiol"},{"issue":"2","key":"4892_CR16","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1128\/AAC.02379-15","volume":"60","author":"KM Kazmierczak","year":"2016","unstructured":"Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE, Biedenbach DJ, Bouchillon SK, Sahm DF, Bradford PA (2016) Multiyear, multinational survey of the incidence and global distribution of metallo-\u03b2-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 60(2):1067\u20131078","journal-title":"Antimicrob Agents Chemother"},{"key":"4892_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1590\/0037-8682-0478-2016","volume":"50","author":"S Amirkamali","year":"2017","unstructured":"Amirkamali S, Naserpour-Farivar T, Azarhoosh K, Peymani A (2017) Distribution of the bla OXA, bla VEB-1, and bla GES-1 genes and resistance patterns of ESBL-producing Pseudomonas aeruginosa isolated from hospitals in Tehran and Qazvin, Iran. Rev Soc Bras Med Trop 50:315\u2013320","journal-title":"Rev Soc Bras Med Trop"},{"issue":"5","key":"4892_CR18","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1093\/jac\/dkr060","volume":"66","author":"C Ge","year":"2011","unstructured":"Ge C, Wei Z, Jiang Y, Shen P, Yu Y, Li L (2011) Identification of KPC-2-producing Pseudomonas aeruginosa isolates in China. J Antimicrob Chemother 66(5):1184\u20131186","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"4892_CR19","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s10096-024-04994-6","volume":"44","author":"C Le Terrier","year":"2025","unstructured":"Le Terrier C, Bouvier M, Kerbol A, Dell\u2019Acqua C, members NN, Nordmann P, Poirel L (2025) In-vitro activity of the novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022. Eur J Clin Microbiol Infect Dis 44(3):571\u2013585","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"4892_CR20","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10096-023-04732-4","volume":"43","author":"C Le Terrier","year":"2024","unstructured":"Le Terrier C, Freire S, Nordmann P, Poirel L (2024) Multidrug-resistant gram-negative clinical isolates with reduced susceptibility\/resistance to cefiderocol: which are the best present and future therapeutic alternatives? Eur J Clin Microbiol Infect Dis 43(2):339\u2013354","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"4892_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3103\/S0891416824700198","volume":"39","author":"A Tozluyurt","year":"2024","unstructured":"Tozluyurt A (2024) The effectiveness of aztreonam, aztreonam-avibactam, cefiderocol on bla NDM-producing E. coli isolates. Mol Genet Microbiol Virol 39(2):158\u2013164","journal-title":"Mol Genet Microbiol Virol"},{"issue":"39","key":"4892_CR22","doi-asserted-by":"publisher","first-page":"27960","DOI":"10.1074\/jbc.M113.485979","volume":"288","author":"DE Ehmann","year":"2013","unstructured":"Ehmann DE, Jahi\u0107 H, Ross PL, Gu R-F, Hu J, Durand-R\u00e9ville TF, Lahiri S, Thresher J, Livchak S, Gao N (2013) Kinetics of avibactam inhibition against class A, C, and D \u03b2-lactamases. J Biol Chem 288(39):27960\u201327971","journal-title":"J Biol Chem"},{"issue":"4","key":"4892_CR23","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1093\/jac\/dkad032","volume":"78","author":"CM Gill","year":"2023","unstructured":"Gill CM, Santini D, Takemura M, Longshaw C, Yamano Y, Echols R, Nicolau DP (2023) In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime\/avibactam, ampicillin\/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii. J Antimicrob Chemother 78(4):983\u2013990","journal-title":"J Antimicrob Chemother"},{"key":"4892_CR24","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.jgar.2020.07.009","volume":"22","author":"N Kohira","year":"2020","unstructured":"Kohira N, Hackel MA, Ishioka Y, Kuroiwa M, Sahm DF, Sato T, Maki H, Yamano Y (2020) Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014). J Glob Antimicrob Resist 22:738\u2013741","journal-title":"J Glob Antimicrob Resist"},{"key":"4892_CR25","doi-asserted-by":"publisher","unstructured":"TozluyurtA,Sahin MC, Acar A (2026) A rare brain abscess caused by co-infection with Fusobacterium nucleatum and Actinomyces meyeri. Wien Med Wochenschr 1\u20138. https:\/\/doi.org\/10.1007\/s10354-025-01126-3","DOI":"10.1007\/s10354-025-01126-3"},{"issue":"3","key":"4892_CR26","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"A-P Magiorakos","year":"2012","unstructured":"Magiorakos A-P, Srinivasan A, Carey RB, Carmeli Y, Falagas M, Giske C, Harbarth S, Hindler J, Kahlmeter G, Olsson-Liljequist B (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268\u2013281","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"4892_CR27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02446-17","volume":"62","author":"WW Nichols","year":"2018","unstructured":"Nichols WW, Newell P, Critchley IA, Riccobene T, Das S (2018) Avibactam pharmacokinetic\/pharmacodynamic targets. Antimicrob Agents Chemother 62(6):10.1128\/aac. 02446\u2009\u2212\u200902417","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"4892_CR28","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/antibiotics11060723","volume":"11","author":"S Karakonstantis","year":"2022","unstructured":"Karakonstantis S, Rousaki M, Kritsotakis EI (2022) Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance. Antibiotics 11(6):723","journal-title":"Antibiotics"},{"issue":"4","key":"4892_CR29","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00039-22","volume":"66","author":"L Poirel","year":"2022","unstructured":"Poirel L, Ortiz de la Rosa J-M, Sadek M, Nordmann P (2022) Impact of acquired broad-spectrum \u03b2-lactamases on susceptibility to cefiderocol and newly developed \u03b2-lactam\/\u03b2-lactamase inhibitor combinations in Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother 66(4):e00039-00022","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"4892_CR30","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/jac\/dkad396","volume":"79","author":"CM Gill","year":"2024","unstructured":"Gill CM, Santini D, Nicolau DP (2024) In vitro activity of cefiderocol against a global collection of carbapenem-resistant Pseudomonas aeruginosa with a high level of carbapenemase diversity. J Antimicrob Chemother 79(2):412\u2013416","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"4892_CR31","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1089\/mdr.2022.0279","volume":"29","author":"MG Wise","year":"2023","unstructured":"Wise MG, Karlowsky JA, Hackel MA, Takemura M, Yamano Y, Echols R, Sahm DF (2023) In vitro activity of cefiderocol against meropenem-nonsusceptible gram-negative bacilli with defined \u03b2-lactamase carriage: SIDERO-WT surveillance studies, 2014\u20132019. Microb Drug Resist 29(8):360\u2013370","journal-title":"Microb Drug Resist"},{"issue":"1","key":"4892_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/1574-6968.12084","volume":"341","author":"M Zienkiewicz","year":"2013","unstructured":"Zienkiewicz M, Kern-Zdanowicz I, Carattoli A, Gniadkowski M, Ceg\u0142owski P (2013) Tandem multiplication of the IS 26-flanked amplicon with the bla SHV-5 gene within plasmid p1658\/97. FEMS Microbiol Lett 341(1):27\u201336","journal-title":"FEMS Microbiol Lett"},{"key":"4892_CR33","doi-asserted-by":"publisher","unstructured":"Choby JE, Ozturk T, Abbott CN, Satola SW, Weiss DS (2022) Heteroresistance via beta-lactamase gene amplification threatens the beta-lactam pipeline. bioRxivChoby, J. E., Ozturk, T., Abbott, C. N., Nnabuife, C., Colquhoun, J. M., Satola, S. W., ... & Weiss, D. S. (2025). Copy number flexibility facilitates heteroresistance to increasing antibiotic pressure and threatens the beta-lactam pipeline. Nature Communications, 16(1), 5721. https:\/\/doi.org\/10.1038\/s41467-025-60828-9","DOI":"10.1038\/s41467-025-60828-9"},{"issue":"10","key":"4892_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00877-21","volume":"65","author":"L Poirel","year":"2021","unstructured":"Poirel L, Sadek M, Nordmann P (2021) Contribution of PER-type and NDM-type \u03b2-lactamases to cefiderocol resistance in Acinetobacter baumannii. Antimicrob Agents Chemother 65(10):10.1128\/aac. 00877\u2009\u2212\u200900821","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"4892_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12030604","volume":"12","author":"G Bianco","year":"2023","unstructured":"Bianco G, Boattini M, Comini S, Banche G, Cavallo R, Costa C (2023) Disc diffusion and ComASP\u00ae cefiderocol microdilution panel to overcome the challenge of cefiderocol susceptibility testing in clinical laboratory routine. Antibiotics 12(3):604","journal-title":"Antibiotics"},{"key":"4892_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.710526","volume":"12","author":"J Zhang","year":"2021","unstructured":"Zhang J, Li G, Zhang G, Kang W, Duan S, Wang T, Li J, Huangfu Z, Yang Q, Xu Y (2021) Performance evaluation of the gradient diffusion strip method and disk diffusion method for ceftazidime\u2013avibactam against Enterobacterales and Pseudomonas aeruginosa: a dual-center study. Front Microbiol 12:710526","journal-title":"Front Microbiol"},{"issue":"3","key":"4892_CR37","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/jac\/dky483","volume":"74","author":"E Wenzler","year":"2019","unstructured":"Wenzler E, Lee M, Wu T, Meyer K, Shields R, Nguyen M, Clancy C, Humphries R, Harrington A (2019) Performance of ceftazidime\/avibactam susceptibility testing methods against clinically relevant Gram-negative organisms. J Antimicrob Chemother 74(3):633\u2013638","journal-title":"J Antimicrob Chemother"}],"container-title":["Current Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-026-04892-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00284-026-04892-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00284-026-04892-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T09:56:01Z","timestamp":1781690161000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00284-026-04892-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4892"],"URL":"https:\/\/doi.org\/10.1007\/s00284-026-04892-4","relation":{},"ISSN":["0343-8651","1432-0991"],"issn-type":[{"value":"0343-8651","type":"print"},{"value":"1432-0991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No ethical approval was required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethical Approval"}}],"article-number":"302"}}